Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082940 · ClinicalTrials.gov registry record · Phase 2
Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00082940 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences.
The verdict
NCT00082940, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies, such as denileukin diftitox, may interfere with the growth of cancer cells and slow the growth of chronic lymphocytic leukemia. PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Interventions
- BIOLOGICAL denileukin diftitox
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-08 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082940
The ClinicalTrials.gov registry entry for NCT00082940 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which denileukin diftitox is the first listed.
NCT00082940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082940 about?
NCT00082940 is a clinical study titled "Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia". RATIONALE: Biological therapies, such as denileukin diftitox, may interfere with the growth of cancer cells and slow the growth of chronic lymphocytic leukemia. PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with fludarabine-refractory B-cell chroni...
What is the current status of trial NCT00082940?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-08. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00082940?
The interventions under investigation include: denileukin diftitox (BIOLOGICAL).
Who is sponsoring clinical trial NCT00082940?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.